Search fresh public links, source activity, and ready-to-use post angles for Kras Inhibitors.
Fresh curated links around KRAS inhibitors are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial, furthering its ambitions to establish divarasib as a...
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
KRAS has long been one of cancer biology’s most stubborn molecular targets. The protein acts as a switch that helps cells interpret growth signals, cycling between an active state...
In a groundbreaking development for appendix cancer treatment, researchers at The University of Texas MD Anderson Cancer Center have unveiled promising results targeting the mutant...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gil...
Roche’s divarasib was designed offer greater potency and selectivity to KRAS G12C compared to first-generation drugs in this class marketed by Amgen and Bristol Myers Squibb. The S...
A Huntsman Cancer Institute team at the University of Utah reports that daraxonrasib, a targeted RAS inhibitor, could offer a new treatment route for a subset of melanoma patients...
The Israeli-developed treatment uses RNA molecules to silence mutated KRAS genes and will be tested alongside standard therapy in patients with locally advanced disease.
An investigational vaccine that targets common KRAS mutations induced durable immune responses among individuals at high risk for pancreatic cancer, results of a phase 1 clinical t...
A first-in-human KRAS-targeted pancreatic cancer prevention vaccine was found to be safe, elicited durable immune responses in 90% of high-risk participants, and showed encouraging...
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for fro...
Ras, one of the cell’s most influential molecular switches, has become the focus of a new live-cell imaging technology designed to reveal where and when the protein is active. In a...
Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & J...
Ipsen is acquiring Kartos Therapeutics to get navtemadlin, which has reached Phase 3 testing in the blood cancer myelofibrosis. The Kartos oral small molecule takes a novel approac...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.